Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026)

Climb Bio filings provide 2 years of Depreciation & Amortization (CF) readings, the most recent being $38000.0 for Q1 2026.

Quarterly Depreciation & Amortization (CF) changed N/A to $38000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $135000.0 through Mar 2026, changed N/A year-over-year, with the annual reading at $97000.0 for FY2025, N/A changed from the prior year.
Depreciation & Amortization (CF) hit $38000.0 in Q1 2026 for Climb Bio, up from $30000.0 in the prior quarter.
Across five years, Depreciation & Amortization (CF) topped out at $38000.0 in Q2 2025 and bottomed at $29000.0 in Q3 2025.